top of page

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapse

FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178). Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

Aktuelle Beiträge

Alle ansehen

Appell des 44. DPT an Lauterbach

Zum Auftakt des 44. Deutschen Psychotherapeutentages (DPT), der am 12. und 13. April in Würzburg stattfindet, richten die Delegierten einen Appell an Bundesgesundheitsminister Prof. Dr. Lauterbach, di

Antiviral defense with new CRISPR tool

As the world prepares for future and ongoing global health threats from RNA viruses such as the SARS-CoV-2 pandemic, breakthrough advances in antiviral development are becoming a critical weapon in th

Commentaires


bottom of page